Related Experiment Videos
[Pharmacokinetics of calcium antagonists]
1Service de Pharmacologie, CHU de Rouen.
Therapie
|November 1, 1993
Summary
Calcium channel blockers have similar absorption and metabolism, but varying half-lives. Different formulations improve patient compliance, efficacy, and reduce side effects for these vital cardiovascular drugs.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Context:
- Calcium channel blockers are a major class of cardiovascular drugs.
- Understanding their pharmacokinetic profiles is crucial for effective therapeutic use.
Purpose:
- To compare the pharmacokinetic properties of different calcium channel blocker classes.
- To highlight how pharmacokinetic variations influence drug formulation and administration.
Summary:
- While resorption, protein binding, and hepatic metabolism are similar across major calcium antagonist classes, plasma elimination half-lives vary significantly.
- Drugs like nifedipine and verapamil have short to intermediate half-lives, often requiring slow-release formulations for once or twice-daily dosing.
- Amlodipine and lacidipine exhibit prolonged action, allowing for once-daily administration due to extended half-lives or cellular accumulation.
Impact:
- Tailored formulations based on pharmacokinetic profiles enhance patient compliance.
- Achieving plateau plasma concentrations leads to improved clinical efficacy.
- Reduced side effects are observed with optimized dosing strategies for calcium channel blockers.